181 related articles for article (PubMed ID: 31871314)
1. The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.
Liao H; Zheng Q; Jin Y; Chozom T; Zhu Y; Liu L; Jiang N
Sci Rep; 2019 Dec; 9(1):19722. PubMed ID: 31871314
[TBL] [Abstract][Full Text] [Related]
2. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
4. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
Blood; 2002 Oct; 100(7):2399-402. PubMed ID: 12239148
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of hematogones in childhood B-cell acute lymphoblastic leukemia.
Arabi S; Yousefian S; Kavosh A; Mansourian M; Nematollahi P
Pediatr Blood Cancer; 2023 Feb; 70(2):e30138. PubMed ID: 36495254
[TBL] [Abstract][Full Text] [Related]
6. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
Cherian S; Soma LA
Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
9. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.
Hassanein NM; Alcancia F; Perkinson KR; Buckley PJ; Lagoo AS
Am J Clin Pathol; 2009 Oct; 132(4):573-80. PubMed ID: 19762535
[TBL] [Abstract][Full Text] [Related]
10. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
11. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of bone marrow hematogones in childhood B-lineage acute lymphoblastic leukemia].
Wang YF; Jiang YM; Gao J; Zhou P; Zhang G
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Apr; 18(4):292-6. PubMed ID: 27097570
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
Saygin C; Papadantonakis N; Cassaday RD; Liedtke M; Fischer K; Dunn T; Patel BJ; Sobecks R; Kalaycio M; Sekeres MA; Mukherjee S; Gerds AT; Hamilton BK; Carraway HE; Advani AS
Leuk Lymphoma; 2018 Feb; 59(2):363-371. PubMed ID: 28693363
[TBL] [Abstract][Full Text] [Related]
14. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
15. The presence of CD34+ cell clusters predicts impending relapse in children with acute lymphoblastic leukemia receiving maintenance chemotherapy.
Rimsza LM; Viswanatha DS; Winter SS; Leith CP; Frost JD; Foucar K
Am J Clin Pathol; 1998 Sep; 110(3):313-20. PubMed ID: 9728605
[TBL] [Abstract][Full Text] [Related]
16. Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).
Chen Z; Ok CY; Wang W; Goswami M; Tang G; Routbort M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2020 Jan; 98(1):36-42. PubMed ID: 31211490
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
19. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
20. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
